Anti-influenza agents

Chakraborty, Sambuddha; Chauhan, Ashwini

doi:10.1016/b978-0-323-91814-5.00006-4

Cited by 2 publications

(1 citation statement)

References 179 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Viral infections and chronic biofilm infections present a difficult challenge for humanity, calling for a strong need to develop anti-viral [ 115 ] and antibiofilm therapies [ 116 ]. The unconjugated and structurally complex glycans, HMOs, have emerged as integral components of the human milk glycome, shaping the immunity and microbial communities of the infant’s gut.…”

Section: Discussionmentioning

confidence: 99%

Human Milk Oligosaccharides as Potential Antibiofilm Agents: A Review

et al. 2022

View full text Add to dashboard Cite

Surface-associated bacterial communities called biofilms are ubiquitous in nature. Biofilms are detrimental in medical settings due to their high tolerance to antibiotics and may alter the final pathophysiological outcome of many healthcare-related infections. Several innovative prophylactic and therapeutic strategies targeting specific mechanisms and/or pathways have been discovered and exploited in the clinic. One such emerging and original approach to dealing with biofilms is the use of human milk oligosaccharides (HMOs), which are the third most abundant solid component in human milk after lactose and lipids. HMOs are safe to consume (GRAS status) and act as prebiotics by inducing the growth and colonization of gut microbiota, in addition to strengthening the intestinal epithelial barrier, thereby protecting from pathogens. Moreover, HMOs can disrupt biofilm formation and inhibit the growth of specific microbes. In the present review, we summarize the potential of HMOs as antibacterial and antibiofilm agents and, hence, propose further investigations on using HMOs for new-age therapeutic interventions.

show abstract

Section: Discussionmentioning

confidence: 99%